Insider · CIK 0001683913
Jane Huang
Files at TARA (Protara Therapeutics, Inc.), PRLD (Prelude Therapeutics Inc). First filing -, latest -.
Jane Huang files SEC Form 4 as president and director at TARA (Protara Therapeutics, Inc.), and also at PRLD (Prelude Therapeutics Inc). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jane Huang has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 15 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | TARA Protara Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +31,000 | $0.00 | $0 | 31,000 | Jun 16, 2026 |
| Oct 4, 2025 | PRLD Prelude Therapeutics Inc | MOption exercise Common Stock | +9,375 | - | - | 90,272 | Oct 7, 2025 |
| Oct 4, 2025 | PRLD Prelude Therapeutics Inc | FTax withholding Common Stock | -3,355 | $1.47 | $4,932 | 86,917 | Oct 7, 2025 |
| Oct 4, 2025 | PRLD Prelude Therapeutics Inc | MOption exercise Restricted Stock Unitderivative | -9,375 | $0.00 | $0 | 18,750 | Oct 7, 2025 |
| Jul 4, 2025 | PRLD Prelude Therapeutics Inc | MOption exercise Common Stock | +9,375 | - | - | 84,252 | Jul 8, 2025 |
| Jul 4, 2025 | PRLD Prelude Therapeutics Inc | FTax withholding Common Stock | -3,355 | $0.79 | $2,664 | 80,897 | Jul 8, 2025 |
| Jul 4, 2025 | PRLD Prelude Therapeutics Inc | MOption exercise Restricted Stock Unitderivative | -9,375 | $0.00 | $0 | 28,125 | Jul 8, 2025 |
| Jun 12, 2025 | TARA Protara Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 13, 2025 |
| Apr 4, 2025 | PRLD Prelude Therapeutics Inc | MOption exercise Common Stock | +9,375 | - | - | 78,232 | Apr 7, 2025 |
| Apr 4, 2025 | PRLD Prelude Therapeutics Inc | FTax withholding Common Stock | -3,355 | $0.68 | $2,265 | 74,877 | Apr 7, 2025 |
| Apr 4, 2025 | PRLD Prelude Therapeutics Inc | MOption exercise Restricted Stock Unitderivative | -9,375 | $0.00 | $0 | 37,500 | Apr 7, 2025 |
| Feb 4, 2025 | PRLD Prelude Therapeutics Inc | AGrant or award Employee Stock Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Feb 5, 2025 |
| Jan 4, 2025 | PRLD Prelude Therapeutics Inc | MOption exercise Common Stock | +9,375 | - | - | 72,716 | Jan 7, 2025 |
| Jan 4, 2025 | PRLD Prelude Therapeutics Inc | FTax withholding Common Stock | -3,859 | $1.39 | $5,364 | 68,857 | Jan 7, 2025 |
| Jan 4, 2025 | PRLD Prelude Therapeutics Inc | MOption exercise Restricted Stock Unitderivative | +9,375 | $0.00 | $0 | 46,875 | Jan 7, 2025 |
Questions about Jane Huang
Answered from the filings on this page, as of the latest one.
Is Jane Huang buying or selling?
Jane Huang has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jane Huang's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jane Huang has 0.
Where does Jane Huang file Form 4?
Jane Huang has filed Form 4 at TARA (Protara Therapeutics, Inc.); PRLD (Prelude Therapeutics Inc) as President, CMO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.